Paper39283290
Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL).
Troiani A and 5 others. Future Oncol, 2024. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL). Papers, record 39283290. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39283290
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL).
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Clinical Trials, Phase I as Topic | Major topic |
| Janus Kinase 1 | Major topic |
| Liver Neoplasms | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Piperidines | |
| Pyrimidines | |
| Treatment Outcome | |
| Neoplasm Staging | |
| Acetonitriles | |
| Pyrazoles | |
| Pyrroles |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Imperial College London | PubMed | |||
| Incyte | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04358185 | Itacitinib in Advanced Hepatocellular Carcinoma | Background | Yes |
Source ClinicalTrials.gov
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22300468 | Management of HCC. | J Hepatol | 2012 | https://conductscience.org/library/papers/22300468 | PubMed |
| 2 | 16207677 | The cancer cachexia syndrome: a review of metabolic and clinical manifestations. | Nutr Clin Pract | 2005 | https://conductscience.org/library/papers/16207677 | PubMed |
| 3 | 34326518 | The immunological and metabolic landscape in primary and metastatic liver cancer. | Nat Rev Cancer | 2021 | https://conductscience.org/library/papers/34326518 | PubMed |
| 4 | 34138876 | Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature. | PLoS One | 2021 | https://conductscience.org/library/papers/34138876 | PubMed |
| 5 | 31449859 | The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. | J Hepatol | 2020 | https://conductscience.org/library/papers/31449859 | PubMed |
| 6 | 27932229 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2017 | https://conductscience.org/library/papers/27932229 | PubMed |
| 7 | 27912061 | Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. | Cell | 2016 | https://conductscience.org/library/papers/27912061 | PubMed |
| 8 | 37499670 | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. | Lancet | 2023 | https://conductscience.org/library/papers/37499670 | PubMed |
| 9 | 17570226 | Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. | Gastroenterology | 2007 | https://conductscience.org/library/papers/17570226 | PubMed |
| 10 | 33479224 | Hepatocellular carcinoma. | Nat Rev Dis Primers | 2021 | https://conductscience.org/library/papers/33479224 | PubMed |
| 11 | 14667750 | Hepatocellular carcinoma. | Lancet | 2003 | https://conductscience.org/library/papers/14667750 | PubMed |
| 12 | 35481940 | Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. | Hepatol Commun | 2022 | https://conductscience.org/library/papers/35481940 | PubMed |
| 13 | 30811474 | Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. | PLoS One | 2019 | https://conductscience.org/library/papers/30811474 | PubMed |
| 14 | 30665869 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30665869 | PubMed |
| 15 | 26769332 | A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. | J Dermatolog Treat | 2016 | https://conductscience.org/library/papers/26769332 | PubMed |
| 16 | 32782275 | Targeted therapy for hepatocellular carcinoma. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/32782275 | PubMed |
| 17 | 25858804 | Immune checkpoint blockade: a common denominator approach to cancer therapy. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25858804 | PubMed |
| 18 | 27789678 | Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. | Haematologica | 2017 | https://conductscience.org/library/papers/27789678 | PubMed |
| 19 | 29624699 | Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. | Hepatology | 2018 | https://conductscience.org/library/papers/29624699 | PubMed |
| 20 | 33061517 | Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis. | Clin Exp Gastroenterol | 2020 | https://conductscience.org/library/papers/33061517 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42022176 | Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42022176 | PubMed |
| 41673081 | Itacitinib in advanced hepatocellular cancer following first line therapy. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/41673081 | PubMed |
| 40620420 | The Diverse Function of IL-6 in Biological Processes and the Advancement of Cancer. | Immune Netw | 2025 | https://conductscience.org/library/papers/40620420 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| JAK1 | 3716 | PubTator's text mining | https://conductscience.org/library/genes/3716 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39283290
GET https://conductscience.org/api/papers/v1/39283290/references?page=2